RITE AID ACCELERATING INTO AUTO PARTS RETAILING WITH ACQUISITION OF ADAP
Executive Summary
RITE AID ACCELERATING INTO AUTO PARTS RETAILING WITH ACQUISITION OF ADAP, a 32-store automotive supply chain operating in New England and based in Avon, Mass. In a March 20 press release announcing the merger, Rite Aid characterized ADAP as "the largest discount automotive after-market retailer in New England." The automotive parts retailer had sales of $34.2 mil. in 1983, which generated net earnings of $1.3 mil., Rite Aid said. The price of the acquisition was not disclosed. Commenting on the acquisition, Rite Aid noted that ADAP "will provide the talent and experience required for expansion in this highly desirable area of specialty retailing." In buying a retail auto parts business, Rite Aid is following a path blazed by several drug chains including Dart and Hook, mutual owners of Trak Auto, and Perry, which last August purchased the 50-store Fleenor's auto parts retail business. Perry is generally credited with being the first drug chain to move into auto parts retailing within its drug store units. The chain later opened 11 stand-alone Auto Works stores before purchasing the Indiana-based Fleenor's last year. Assuming that the price paid for ADAP as a ratio to sales is roughly similar to what Perry paid for Fleenor's, the price tag for ADAP was probably in the $6 mil.-$8 mil. range -- and possibly higher since ADAP was considerably more profitable at the time of purchase.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth